Comparisons of in-hospital fee and surgical outcomes between robot-assisted, laparoscopic, and open radical cystectomy: a Japanese nationwide study

Minato Yokoyama,Wei Chen,Yuma Waseda,Motohiro Fujiwara,Daisuke Kato,Takeshi Shirakawa,Yohei Shimizu,Tsunehiro Nenohi,Yuki Matsumoto,Taisuke Okumura,Masayasu Urushibara,Masumi Ai,Kiyohide Fushimi,Takashi Fukagai,Masatoshi Eto,Yasuhisa Fujii,Kazuhiro Ishizaka

DOI: https://doi.org/10.1093/jjco/hyae039

IF: 2.925

2024-03-28

Japanese Journal of Clinical Oncology

Abstract:Abstract Objective To evaluate in-hospital fees and surgical outcomes of robot-assisted radical cystectomy (RARC), laparoscopic radical cystectomy (LRC) and open radical cystectomy (ORC) using a Japanese nationwide database. Methods All data were obtained from the Diagnosis Procedure Combination database between April 2020 and March 2022. Basic characteristics and perioperative indicators, including in-hospital fees, were compared among the RARC, LRC and ORC groups. Propensity score–matched comparisons were performed to assess the differences between RARC and ORC. Results During the study period, 2931, 1311 and 2435 cases of RARC, LRC and ORC were identified, respectively. The RARC group had the lowest in-hospital fee (median: 2.38 million yen), the shortest hospital stay (26 days) and the lowest blood transfusion rate (29.5%), as well as the lowest complication rate (20.9%), despite having the longest anesthesia time (569 min) among the three groups (all P < 0.01). The outcomes of LRC were comparable with those of RARC, and the differences in these indicators between the RARC and ORC groups were greater than those between the RARC and LRC groups. In propensity score–matched comparisons between the RARC and ORC groups, the differences in the indicators remained significant (all P < 0.01), with an ~50 000 yen difference in in-hospital fees. Conclusions RARC and LRC were considered to be more cost-effective surgeries than ORC due to their superior surgical outcomes and comparable surgical fees in Japan. The widespread adoption of RARC and LRC is expected to bring economic benefits to Japanese society.

oncology